1.045

6.05% 0.055

Palatin Technologies Inc. (PTN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Palatin Technologies Inc. stock is traded at $1.045, with a volume of 2.16M. It is up +6.05% in the last 24 hours and down -13.23% over the past month. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Previous Close:

$0.99

Open:

$1.02

24h Volume:

2.16M

Relative Volume:

2.95

Market Cap:

$24.63M

Revenue:

$7.10M

Net Income/Loss:

$-31.59M

P/E Ratio:

-0.4004

EPS:

-2.61

Net Cash Flow:

$-26.75M

1W Performance:

+15.18%

1M Performance:

-13.23%

6M Performance:

-23.36%

1Y Performance:

-74.33%

1-Day Range:

$1.01

$1.15

1-Week Range:

$0.79

$1.38

52-Week Range:

$0.68

$4.65

Palatin Technologies Inc. Stock (PTN) Company Profile

Name

Palatin Technologies Inc.

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

609-495-2200

Address

Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ

Employee

Twitter

@PalatinTech

Next Earnings Date

2024-11-12

Latest SEC Filings

PTN's Discussions on Twitter

Compare PTN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTN Palatin Technologies Inc.	1.05	24.63M	7.10M	-31.59M	-26.75M	-2.61
VRTX Vertex Pharmaceuticals Inc	469.58	122.13B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	713.96	78.30B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	648.08	39.73B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.20	35.50B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.33	28.47B	3.30B	-501.07M	1.03B	-2.1146

Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-15	Reiterated	Canaccord Genuity	Buy
Jan-12-15	Reiterated	ROTH Capital	Buy
May-23-12	Initiated	Noble Financial	Buy
Jan-23-07	Initiated	Next Generation	Buy

Palatin Technologies Inc. Stock (PTN) Latest News

10:21 AM

Palatin Gains on New Offering - Baystreet.ca

10:21 AM

09:12 AM

Palatin Technologies Announces $4.7 Mln Direct Offering - Nasdaq

09:12 AM

08:20 AM

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement - Marketscreener.com

08:20 AM

08:10 AM

Palatin secures $4.7 million in stock and warrant sale - Investing.com

08:10 AM

08:06 AM

Palatin secures $4.7 million in stock and warrant sale By Investing.com - Investing.com UK

08:06 AM

08:00 AM

Palatin's Strategic $4.7M Healthcare Investment Deal: Inside the Critical Financing Terms - StockTitan

08:00 AM

06:31 AM

Palatin concludes Phase II trial of combination therapy for obesity - Clinical Trials Arena

06:31 AM

01:38 AM

As Saudi Arabia’s Tourism Sector Grows Exponentially, dmg events Announces Hotel & Hospitality Expo - GlobeNewswire Inc.

01:38 AM

01:24 AM

Palatin finishes phase 2 trial in obesity treatment study By Investing.com - Investing.com Nigeria

01:24 AM

Feb 06, 2025

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide - GuruFocus.com

Feb 06, 2025

Palatin finishes phase 2 trial in obesity treatment study - Investing.com

Feb 06, 2025

Obesity Treatment Breakthrough? Palatin's Novel GLP-1 Combo Trial Wraps Up With Massive Patient Interest - StockTitan

Feb 06, 2025

Feb 04, 2025

PTN’s price-to-sales ratio: A comparative analysis with its peers - US Post News

Feb 04, 2025